Similar Posts
Kirkland Chocolate Chips Are Back, Baby! But …
Amanda Barroso writes for NerdWallet. Email: abarroso@nerdwallet.com. The article Kirkland Chocolate Chips Are Back, Baby! But … originally appeared on NerdWallet.
Childhood Cognitive and Behavioral Impairments and Adult Health
This work was supported by the National Center for Advancing Translational Sciences, National Institutes of Health under award number UM1TR004789, the Robert Wood Johnson Foundation through its support of the Child Health Institute of New Jersey under grant number 74260, and the Center for Health and Wellbeing at Princeton University. The funders/sponsors had no role…
U.S. GAO – U.S. Army’s Efforts to Modernize Artillery, Missiles for a New Era of Warfare
Thursday, June 5, 2025 U.S. Army’s Efforts to Modernize Artillery, Missiles for a New Era of Warfare The U.S. Army is shifting its focus from counterinsurgency-style warfare to large scale combat operations. And with this shift comes an urgent need for artillery and missile systems that are more mobile, durable and more lethal than what…
SEC Charges 38 Alleged Scammers of Fake Filings
The Securities and Exchange Commission has charged 38 entities in a Colorado court with making material misrepresentations in Form ADVs filed between 2025 and 2026 for allegedly falsely portraying themselves as legitimate advisory firms to U.S. investors, the agency said Friday. The 38 complaints, filed against each individual defendant, allege that some used IP addresses…
Elon Musk Just Explained Why Memory Could Be the Next AI Winner.
Elon Musk says that the artificial intelligence build-out has a memory problem. The CEO of Tesla and Space Exploration Technologies (SPCX -7.81%) said on SpaceX’s earnings call that demand for memory chips is growing much faster than the available supply. “The limiting factor currently is memory,” he said. Musk’s statement is notable for two reasons….
AstraZeneca’s trial flop raises bigger questions around its pipeline
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the company. Most analysts estimate the trial miss wiped just 2-4% from their valuation models. Yet the shares lost roughly twice that in a single session, suggesting the market reaction reflected more than just the loss of one drug,…